PepGen Inc.
PEPGNasdaq
$2.25
0.0%Jul 17 close · end-of-day
Price
1Y↑ +75.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$155.5M
Enterprise Value
$23.2M
P/E
—
P/S
—
P/B
1.2
EV/EBITDA
—
PEG
—
FCF Yield
-49.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$77.2M
Free Cash Flow (TTM)
-$77.3M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-57.6%
ROIC
-3826.7%
Debt / Equity
—
Net Cash
$132.3M
Return 1Y
+66.7%
Company profile
PepGen Inc. focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy.
- CEO
- James G. McArthur
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 30
- Headquarters
- Massachusetts
- Website
- pepgen.com
Management & directors
- Kasraian KasraChief Technical Officer
- Donnelly NoelChief Financial Officer
- Mcarthur James GPresident and CEO
- Streck PaulEVP, Head of R&D
- Vittiglio JosephChief Business & Legal Officer
Roles derived from SEC Form 4 filings.
Earnings
PEPG Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.26↓ -71.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$27.1M | -$68.3M | -$84.8M | -$97.7M | -$93.6M |
| Net income | -$27.3M | -$69.1M | -$78.6M | -$90.0M | -$89.7M |
| Diluted EPS | -$30.27 | -$4.42 | -$3.30 | -$2.85 | -$2.12 |
| Operating cash flow | -$22.6M | -$59.3M | -$69.0M | -$82.4M | -$81.6M |
| Free cash flow | -$23.1M | -$63.0M | -$71.6M | -$82.9M | -$81.9M |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$30.4M | -$23.2M | -$24.3M | -$31.3M | -$23.9M | -$18.7M | -$19.7M | -$18.9M |
| Net income | -$28.3M | -$21.4M | -$22.2M | -$30.2M | -$23.1M | -$18.0M | -$18.3M | -$17.8M |
| Diluted EPS | -$0.87 | -$0.66 | -$0.69 | -$0.92 | -$0.70 | -$0.52 | $0.02 | -$0.26 |
| Operating cash flow | -$16.4M | -$24.0M | -$19.5M | -$22.9M | -$23.6M | -$19.3M | -$15.8M | -$18.4M |
| Free cash flow | -$16.4M | -$24.2M | -$19.7M | -$23.1M | -$23.6M | -$19.4M | -$15.8M | -$18.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 18, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-21 | Kasraian Kasra· Chief Technical Officer | Sale | 1,233 | $1.41 | $1,739.39 | filing |
| 2026-03-04 | McArthur James G· President and CEO | Sale | 5,144 | $6.23 | $32,047.12 | filing |
| 2026-03-04 | Donnelly Noel· Chief Financial Officer | Sale | 2,032 | $6.23 | $12,659.36 | filing |
| 2026-03-04 | STRECK PAUL· EVP, Head of R&D | Sale | 1,832 | $6.23 | $11,413.36 | filing |
| 2026-03-04 | McArthur James G· President and CEO | Sale | 131 | $6.33 | $828.58 | filing |
| 2026-03-04 | Donnelly Noel· Chief Financial Officer | Sale | 52 | $6.33 | $328.90 | filing |
| 2026-03-04 | STRECK PAUL· EVP, Head of R&D | Sale | 47 | $6.29 | $295.54 | filing |
| 2026-03-01 | Vittiglio Joseph· Chief Business & Legal Officer | Award | 30,717 | $0.00 | $0.00 | filing |
| 2026-03-01 | Kasraian Kasra· Chief Technical Officer | Award | 34,557 | $0.00 | $0.00 | filing |
| 2026-03-01 | STRECK PAUL· EVP, Head of R&D | Award | 50,300 | $0.00 | $0.00 | filing |
| 2026-03-01 | Donnelly Noel· Chief Financial Officer | Award | 76,793 | $0.00 | $0.00 | filing |
| 2026-03-01 | McArthur James G· President and CEO | Award | 187,688 | $0.00 | $0.00 | filing |
| 2025-12-08 | Vittiglio Joseph· Chief Business & Legal Officer | Award | 35,000 | $0.00 | $0.00 | filing |
| 2025-09-30 | Oxford Sciences Innovation plc | Buy | 200,000 | $3.20 | $640,000.00 | filing |
| 2025-09-26 | RA CAPITAL MANAGEMENT, LLC | Buy | 9,375,000 | $3.20 | $30.0M | filing |
Latest 15 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.